Business Wire
Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen | Business Wire
March 23, 2021 - Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results sho
Business Wire
Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results | Business Wire
August 12, 2021 - We are now completing a thorough analysis of our FX-322 exploratory clinical studies, which has served to increase our understanding of the etiologies and severities where hearing benefits have been observed in study subjects.
Frequencytx
Hearing Loss Treatment | Multiple Sclerosis | Frequency ...
Pioneering RNA editing to deliver the future of medicine · RNA editing holds great promise to rewrite what’s possible for patients. Since the discovery of the first generation of editing technologies, researchers have been working to overcome the inherent complexity of these initial approaches ...
Yahoo!
Frequency Therapeutics, Inc. (FREQ) Misstated the Potential of its Hearing Loss Treatment FX-322
July 28, 2021 - According to the complaint, Frequency Therapeutics began its Phase 2a trial for FX-322 in October 2019. The trial results failed to live up to the Company's expectations, as they revealed no discernable difference between FX-322 and the placebo. However, the Company continued to conduct the ...
Business Wire
Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322 | Business Wire
February 23, 2021 - Individuals with stable SNHL that received a single dose of FX-322 showed improvements in the number of words recognized in quiet from baseline to day 90 in the WR test (p=0.029) and the level of background noise in which words could be identified in the WIN test (p=0.012).
YouTube
The CURE for Hearing Loss: Part 2 | FX 322 Drug - YouTube
07:12
The CURE for Hearing Loss: Part 2 | FX-322 Drug. Dr. Cliff Olson, Audiologist and founder of Applied Hearing Solutions in Phoenix Arizona, discusses the pro...
Published: September 29, 2020
Views: 32K
BioSpace
Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322 | BioSpace
February 23, 2021 - (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the publication of its FX-322 Phase 1/2 study results in Otology & Neurotology, a leading ...
BioSpace
Frequency Therapeutics Announces Expanded FX-322 ...
October 30, 2020 - Company Will Report Data from Phase 2a Sensorineural Hearing Loss (SNHL) Study in Late Q1 2021 First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter
MassDevice
Frequency Therapeutics drug shows promise in restoring hearing in small study - MassDevice
March 18, 2021 - Frequency Therapeutics (Woburn, Mass.) recently announced promising data related to its experimental FX-322 drug.
Yahoo! Finance
Frequency Therapeutics Stock Craters After FX-322's Four Weekly Regime Shows No Benefit In Sensorineural Hearing Loss
March 25, 2021 - Frequency Therapeutics Inc (NASDAQ: FREQ) stock plunges in the premarket after reporting topline day-90 data from its Phase 2a study (FX-322-202) evaluating the company's lead product candidate FX-322 in sensorineural hearing loss (SNHL). What Happened: Final results from the Phase 2a study ...